Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

Treatment benefit in multiple myeloma (MM) patients with high‐risk cytogenetics remains suboptimal. The phase 3 ICARIA‐MM trial (NCT02990338) showed that isatuximab plus pomalidomide–dexamethasone prolongs median progression‐free survival (mPFS) in patients with relapsed/refractory MM (RRMM). This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Simon J., Perrot, Aurore, Alegre, Adrian, Simpson, David, Wang, Ming Chung, Spencer, Andrew, Delimpasi, Sosana, Hulin, Cyrille, Sunami, Kazutaka, Facon, Thierry, Vlummens, Philip, Yong, Kwee, Campana, Frank, Inchauspé, Marlène, Macé, Sandrine, Risse, Marie‐Laure, van de Velde, Helgi, Richardson, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematological malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361732/
https://www.ncbi.nlm.nih.gov/pubmed/34036560
http://dx.doi.org/10.1111/bjh.17499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361732/
https://www.ncbi.nlm.nih.gov/pubmed/34036560
http://dx.doi.org/10.1111/bjh.17499

Ejemplares similares